A Phase II, Open Label, Multicenter Trial of Venetoclax (ABT-199/GDC-0199) as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal T-cell Lymphomas of T-follicular Helper Origin (TFH)
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 26 Nov 2019 Planned End Date changed from 15 Nov 2020 to 31 May 2021.
- 26 Nov 2019 Planned primary completion date changed from 15 Nov 2019 to 31 Aug 2020.
- 06 Feb 2019 Status changed from not yet recruiting to recruiting.